Page 5 - Nasdaq Cgem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee...

CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee...

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) – Research analysts at SVB Leerink raised their Q2 2022 earnings per share (EPS) estimates for shares of Cullinan Oncology in a report released on Monday, May 16th. SVB Leerink analyst A. Berens now forecasts that the company will post earnings per share of $5.44 for the quarter, […]

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Vision Scs F2 sold 35,158 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $11.23, for a total transaction of $394,824.34. Following the transaction, the insider now directly owns 1,305,873 shares in the company, […]

Cullinan Oncology (NASDAQ:CGEM – Get Rating) and BioNTech (NASDAQ:BNTX – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Volatility and Risk Cullinan Oncology has a beta of 0.22, indicating […]